,Canonical_Smiles,drug_name,drug_type,Label
0,COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-],Nifedipine,3A4-Inducer,positive
1,COc1cc2nc(N(C)CCCNC(=O)[C@H]3CCCO3)nc(N)c2cc1OC,Alfuzosin,3A4-Substrate,negative
2,CC(Nc1cc(-c2[nH]c(S(C)=O)nc2-c2ccc(F)cc2)ccn1)c1ccccc1,ML_3603,2D6-Substrate,negative
3,CN(C)CCO,Deanol,Methyltransferase-Substrate,negative
4,OCC(CO)N[C@H]1C[C@@](O)(CO)[C@H](O)[C@@H](O)[C@@H]1O,Voglibose,2E1-Inducer,negative
5,Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,Raltegravir,UGT-Substrate,negative
6,CCC[C@@H](C)C1(CC)C(=O)NC(=O)NC1=O,Pentobarbital,-,negative
7,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C,Norethisterone,P450_HFLA-Substrate,negative
8,CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,Clomifene,19A-Inhibitor,negative
9,COc1ccccc1OCCNC[C@H](O)COc1cccc2[nH]c3ccccc3c12,carvedilol_S,2D6-Substrate,negative
10,CCCCOC(=O)C(=O)Nc1cccc(-c2nn[nH]n2)c1,Tazanolast,-,negative
11,CCN(CC)CC#CCOC(=O)[C@@](O)(c1ccccc1)C1CCCCC1,Oxybutynin,2D6-Inhibitor,negative
12,COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,Atazanavir,P450_HFLA-Inhibitor,negative
13,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,Ergoloid Mesylates,Solute_carrier_organic_anion_transporter_family_member_2B1-Inhibitor,negative
14,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,Hydrocortisone,3A4-Inducer,positive
15,CN1C2CCC1CC(NC(=O)c1cc(Cl)cc3c1OC(C)(C)C3)C2,Zatosetron,-,negative
16,ClC1=C(Cl)C2(Cl)C3C4CC(C5OC45)C3C1(Cl)C2(Cl)Cl,Dieldrin,-,negative
17,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)C=C(C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)C=CC=CC=C1C,Everolimus,-,negative
18,O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,thalidomide,2C19-Substrate,negative
19,CN(C)c1ccc([C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,onapristone,3A4-Substrate,negative
20,Nc1nc(C(=CCC(=O)O)C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=CCS[C@@H]23)cs1,Ceftibuten,Solute_carrier_family_15_member_1-Substrate,negative
21,CCOc1ccccc1O[C@@H](c1ccccc1)[C@@H]1CNCCO1,Reboxetine,2D6-Inducer,negative
22,CC(C)NC[C@H](O)COc1ccc(CCOCC2CC2)cc1,Betaxolol,2D6-Substrate,negative
23,CN1CCN(C(=O)O[C@@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,Zopiclone,2E1-Substrate,negative
24,CCNC(=O)[C@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H]1CCC(=O)N1,Buserelin,19A-Inducer,negative
25,O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,Cetirizine,-,negative
26,c1ccc2ncccc2c1,quinoline,2E1-Substrate,negative
27,CCCCCn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_4,3A4-Substrate,negative
28,CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@@H]3C[C@@H]12,Tetracycline,GST-Inhibitor,negative
29,CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1,Sufentanil,-,negative
30,NC(N)=O,Carbamide,2E1-Inducer,negative
31,COc1cc2c(c(OC)c1OC)-c1c(cc(OC)c(OC)c1OC)C[C@@H](C)[C@@H](C)C2,deoxy_schizandrin,3A4-Substrate,negative
32,CCN[C@@H](C)Cc1ccccc1,Etilamfetamine,2D6-Substrate,negative
33,C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,Bicalutamide,2D6-Inhibitor,negative
34,C[C@H](CCC(=O)O)[C@@H]1CC[C@H]2[C@H]3[C@H](CC[C@]12C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,chenodeoxycholic_acid,3A4-Substrate,negative
35,CO[C@@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,Artemether,2D6-Substrate,negative
36,Nc1ccc(S(N)(=O)=O)cc1,Sulfanilamide,2E1-Inhibitor,negative
37,COc1cc(CNC(=O)CCCCC=CC(C)C)ccc1O,Capsaicin,2E1-Substrate,negative
38,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)[C@@H]2N[C@@H](COCCOC)O[C@H]([C@H]2C)[C@]1(C)O,Dirithromycin,-,negative
39,CC(C)N=C(N)N=C(N)Nc1ccc(Cl)c(Cl)c1,Chlorproguanil,-,negative
40,C[N+](C)(C)CCOC(N)=O,Carbachol,N_acetyltransferase-Inhibitor,negative
41,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)C1=O,9_alpha_fluoro_androstadienedione,3A4-Substrate,negative
42,CCCCNC(C)Cc1ccc(OC)cc1,4_methoxy_N_butylamphetamine,2D6-Substrate,negative
43,ClC=C(Cl)Cl,Trichloroethylene,2E1-Substrate,negative
44,CCC(=C(c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,Tamoxifen,3A4-Inducer,positive
45,CN(C)CCCN1c2ccccc2CCc2ccccc21,Imipramine,CP2CI-Substrate,negative
46,CCC1=C(C)CN(C(=O)NCCc2ccc(S(=O)(=O)NC(=O)N[C@H]3CC[C@H](C)CC3)cc2)C1=O,Glimepiride,-,negative
47,CN[C@@H](C)Cc1ccccc1,Metamfetamine,2D6-Substrate,negative
48,Cc1ccnc(NS(=O)(=O)c2ccc(N)cc2)n1,Sulfamerazine,-,negative
49,Cc1c(C)c2c(c(C)c1O)CC[C@](C)(COc1ccc(C[C@@H]3SC(=O)NC3=O)cc1)O2,Troglitazone,3A4-Inducer,positive
50,C/C=C1/C[C@@H](C)[C@@](C)(O)C(=O)OCC2=CCN3CC[C@@H](OC1=O)[C@@H]23,senecionine,3A4-Substrate,negative
51,CC(C)NC[C@@H](O)COc1ccc(COCCOC(C)C)cc1,Bisoprolol,2D6-Substrate,negative
52,Cc1ccc(C)cc1,xylene_para,2E1-Substrate,negative
53,C[C@@H](C(=O)O)c1ccc(C(=O)c2cccs2)cc1,suprofen_R,2C9-Substrate,negative
54,O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,apigenin,1A2-Substrate,negative
55,CCOc1ccc2c(Cl)cc(=O)oc2c1,4_chloro_7_ethoxycoumarin,2C19-Substrate,negative
56,CC(C)(C)NCC(O)COc1ccccc1C1CCCC1,Penbutolol,2D6-Substrate,negative
57,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1c1cccc2nonc12,Isradipine,-,negative
58,COC(F)(F)C(Cl)Cl,Methoxyflurane,2E1-Substrate,negative
59,CCC(=O)O[C@](Cc1ccccc1)(c1ccccc1)[C@H](C)CN(C)C,Dextropropoxyphene,P450_HFLA-Inducer,negative
60,CCCCCCCCCCCCCCCCCC(=O)O,stearic_acid,2E1-Substrate,negative
61,CN(C)Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,Adinazolam,-,negative
62,Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,Zidovudine,-,negative
63,N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,Chlorhexidine,Methyltransferase-Inhibitor,negative
64,CCCC(C)Cn1c(=O)c2c(ncn2C)n(C)c1=O,theobromine_deriv_8,3A4-Substrate,negative
65,O=C1OC2(c3ccc(OCc4ccccc4)cc3Oc3cc(OCc4ccccc4)ccc32)c2ccccc21,dibenzyl_fluorescein,2D6-Substrate,negative
66,CN(CCOc1ccc(C[C@@H]2SC(=O)NC2=O)cc1)c1ccccn1,Rosiglitazone,2D6-Inhibitor,negative
67,CCCOCCOC(=O)C1=C(C)NC(C)=C(C(=O)OCCOCCC)C1c1cccc([N+](=O)[O-])c1,Niludipine,-,negative
68,C1=CCCCC1,cyclohexene,2E1-Substrate,negative
69,Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,Imatinib,P450_HFLA-Substrate,negative
70,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C,Cyproterone,19A-Inhibitor,negative
71,C[C@@H]1CNc2c(cccc2S(=O)(=O)N[C@@H](CCCNC(=N)N)C(=O)N2CC[C@@H](C)C[C@@H]2C(=O)O)C1,Argatroban,Methyltransferase-Inducer,negative
72,COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)cc1,muraglitazar,2E1-Substrate,negative
73,CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O,Resiquimod,-,negative
74,O=C(O)COc1ccc(C(=O)c2cccs2)c(Cl)c1Cl,Tienilic Acid,GST-Inhibitor,negative
75,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2C(=O)CO,Desoxycortone,Steroid_11_beta_hydroxylase-Substrate,negative
76,CCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,Methylprednisolone Aceponate,3A4-Inducer,positive
77,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC=Cc2ccccc2)[C@H]1c1cccc([N+](=O)[O-])c1,Cilnidipine,-,negative
78,CCC1(C)CC(OC(=O)CSc2n[nH]c(N)n2)C2(C)C(C)CCC3(CCC(=O)C32)C(C)C1O,Azamulin,-,negative
79,CN1CCN(c2cc3c(cc2F)c(=O)c(C(=O)O)cn3-c2ccc(F)cc2)CC1,Difloxacin,-,negative
80,CC(N)C(=O)c1ccccc1,Cathinone,-,negative
81,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@@H]2C[C@](C)(OC)[C@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@H]2O[C@@H](C)C[C@H](N(C)C)[C@@H]2O)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,Roxithromycin,-,negative
82,CCOC(=O)c1ccc(N)cc1,Benzocaine,2E1-Inhibitor,negative
83,CC(C)(N)Cc1ccccc1,Phentermine,2D6-Inhibitor,negative
84,CC1(C)[C@H](C=C(Cl)Cl)[C@H]1C(=O)O[C@H](C#N)c1cccc(Oc2ccccc2)c1,Cypermethrin,1A2-Substrate,negative
85,O=C1C[C@H](c2ccc(O)cc2)Oc2cc(O)cc(O)c21,naringenin,1A2-Substrate,negative
86,CC1=CC(=O)[C@@H]2C[C@H]1C2(C)C,Levoverbenone,2B6-Substrate,negative
87,CN1[C@H]2CCC[C@@H]1C[C@@H](NC(=O)c1nn(C)c3ccccc13)C2,Granisetron,2D6-Substrate,negative
88,CN1CCc2cccc3c2[C@H]1Cc1ccc(O)c(O)c1-3,Apomorphine,SUL-Substrate,negative
89,NCCc1c[nH]cn1,Histamine,2E1-Inducer,negative
90,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,Telithromycin,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
91,O=C1C=C2CN(C(C(=O)C3CC3)c3ccccc3F)CCC2S1,R_95913,2D6-Substrate,negative
92,CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,taxol,2C8-Substrate,negative
93,COc1ccc(CCNCCC[C@@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,norverapamil_S,2C8-Substrate,negative
94,CCOc1ccc2c(C(F)(F)F)cc(=O)oc2c1,7_ethoxy_4_trifluoro_methyl_coumarin,2E1-Substrate,negative
95,NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O,Chlorothiazide,Solute_carrier_family_22_member_8-Substrate,negative
96,CCCCOC(=O)c1ccccc1C(=O)OCCCC,Dibutylphthalate,19A-Inducer,negative
97,Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,lansoprazole_R,2C19-Substrate,negative
98,O=C(O)CC[C@H]1[C@@H](NS(=O)(=O)c2ccccc2)C2CC[C@@H]1C2,tetranor,2C9-Substrate,negative
99,C=C1C(=CC=C2CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@H](O)C[C@H]1O,Alfacalcidol,Sterol_26_hydroxylase_Sterol_27_hydroxylase_Vitamin_D3_25_hydroxylase_5_beta_cholestane_3_alpha_7_alpha12_alpha_triol_27_hydroxylase-Substrate,negative
100,CCCCN(CCCC)CC[C@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12,Halofantrine,2D6-Inhibitor,negative
101,NC(N)=Nc1nc(CSCCC(N)=NS(N)(=O)=O)cs1,Famotidine,-,negative
102,Oc1ccccc1,Phenol,2E1-Substrate,negative
103,CCCCN(CCCC)N=O,NN_dibutyl_nitrosoamine,2E1-Substrate,negative
104,Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,Clotrimazole,3A4-Inducer,positive
105,CSc1nc(-c2ccnc(NC(C)c3ccccc3)c2)c(-c2ccc(F)cc2)[nH]1,ML_3403,2D6-Substrate,negative
106,Cc1c[nH]c2ccccc12,3_methylindole,2E1-Substrate,negative
107,CN(CCCN1c2ccccc2CCc2ccccc21)CC(=O)c1ccc(Cl)cc1,Lofepramine,2D6-Substrate,negative
108,COc1ccc(CCN(C)CCC[C@](C#N)(c2ccc(OC)c(OC)c2)C(C)C)cc1OC,verapamil_R,2C8-Substrate,negative
109,Cc1cccc(C)c1NC(=O)[C@H](C)N,Tocainide,-,negative
110,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@@H]1c1cccc([N+](=O)[O-])c1,Nimodipine,-,negative
111,O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,Mitoxantrone,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
112,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,Saxagliptin,3A4-Substrate,negative
113,CCCN1CCCC2Cc3nc(N)ncc3CC21,Quinelorane,-,negative
114,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc2c1OCO2,Oxodipine,-,negative
115,CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,Amoxicillin,Solute_carrier_family_22_member_6-Substrate,negative
116,CCCC(=O)Nc1ccc(OC[C@@H](O)CNC(C)C)c(C(C)=O)c1,Acebutolol,2D6-Inhibitor,negative
117,CC(C)NC[C@H]1CCc2cc(CO)c([N+](=O)[O-])cc2N1,Oxamniquine,2D6-Inhibitor,negative
118,COC(=O)[C@H]1[C@@H](O)CC[C@H]2CN3CCc4c([nH]c5ccccc45)[C@@H]3C[C@@H]21,Yohimbin,2D6-Inhibitor,negative
119,CCOC(=O)Nc1ccc2c(c1)N(C(=O)CCN1CCOCC1)c1ccccc1S2,Moracizine,-,negative
120,O=c1n(CCCN2CCN(c3cccc(Cl)c3)CC2)nc2ccccn12,Trazodone,P450_HFLA-Substrate,negative
121,CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1c1cccc(Cl)c1Cl,Felodipine,P450_HFLA-Substrate,negative
122,CCOP(=S)(OCC)Oc1cc(C)nc(C(C)C)n1,diazinion,2E1-Substrate,negative
123,C[C@H](CN(C)C)CN1c2ccccc2S(=O)(=O)c2ccccc21,Oxomemazine,3A4-Inducer,positive
124,Cc1ccc(Cl)c(OC[C@@H](O)CNC(C)(C)C)c1,Bupranolol,2D6-Substrate,negative
125,Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,Dasatinib,UGT-Inhibitor,negative
126,O=C(c1cccs1)c1ccc(OCCCO)c(Cl)c1Cl,tienilic_acid_deriv_3,2C19-Substrate,negative
127,CN1CCCC[C@H]1CCN1c2ccccc2Sc2ccc(S(C)=O)cc21,Mesoridazine,2D6-Substrate,negative
128,CNCCC[C@]12CC[C@H](c3ccccc31)c1ccccc12,Maprotiline,2D6-Substrate,negative
129,O=C(O[C@@H]1C[C@@H]2C[C@@H]3C[C@H](C1)N2CC3=O)c1c[nH]c2ccccc12,Dolasetron,2D6-Substrate,negative
130,CCN(CC)CCOC(=O)C1(C2CCCCC2)CCCCC1,Dicycloverine,Methyltransferase-Inhibitor,negative
131,CCC1(c2ccccc2)C(=O)NC(=O)NC1=O,Phenobarbital,3A4-Inducer,positive
132,Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1,Sulfadiazine,2E1-Substrate,negative
133,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,Azithromycin,-,negative
134,COc1ccc2cc(CCC(C)=O)ccc2c1,nabumetone,2E1-Substrate,negative
135,CCC(N)Cc1ccc2c(c1)OCO2,BDB,2D6-Substrate,negative
136,Cc1c2oc3c(C)ccc(C(=O)N[C@H]4C(=O)N[C@@H](C(C)C)C(=O)N5CCC[C@@H]5C(=O)N(C)CC(=O)N(C)[C@H](C(C)C)C(=O)O[C@H]4C)c3nc-2c(C(=O)N[C@H]2C(=O)N[C@@H](C(C)C)C(=O)N3CCC[C@@H]3C(=O)N(C)CC(=O)N(C)[C@H](C(C)C)C(=O)O[C@H]2C)c(N)c1=O,Dactinomycin,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
137,CC1=CC(=O)C=C2CCC3C4CCC(=O)C4(C)CCC3C12C,Atamestane,-,negative
138,CN(CCCC(=O)c1cccnc1)N=O,NNK,2E1-Substrate,negative
139,CNC(=O)Oc1cc(C)c(SC)c(C)c1,Methiocarb,2D6-Substrate,negative
140,C[C@]12CC[C@@H]3[C@H]4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@H]2O,Nandrolone,19A-Substrate,negative
141,CSc1ccc2c(c1)N(CC[C@@H]1CCCCN1C)c1ccccc1S2,Thioridazine,2E1-Inhibitor,negative
142,C[C@H](CN(C)C)CN1c2ccccc2Sc2ccc(C#N)cc21,Cyamemazine,2C9-Substrate,negative
143,Cc1ccc(O)cc1,p_cresol,2E1-Substrate,negative
144,OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,Fluconazole,3A4-Inducer,positive
145,O=c1[nH]cc(F)c(=O)[nH]1,Fluorouracil,-,negative
146,NS(=O)(=O)Cc1noc2ccccc12,Zonisamide,-,negative
147,CN1CCCCC1CCN1c2ccccc2Sc2ccc(S(C)=O)cc21,mesoridazine,2D6-Substrate,negative
148,CC(NCC(O)COc1cccc2ccccc12)C(F)(F)F,trifluoro_propranolol,2D6-Substrate,negative
149,O=C(O)CCC/C=C\C[C@@H]1[C@@H](NS(=O)(=O)c2ccccc2)C2CC[C@@H]1C2,S_145,2C9-Substrate,negative
150,Cc1cc(-c2ccccc2)nnc1NCCN1CCOCC1,Minaprine,2D6-Substrate,negative
151,COc1c(C)c2c(c(O)c1CC=C(C)CCC(=O)O)C(=O)OC2,Mycophenolic Acid,Solute_carrier_family_22_member_6-Substrate,negative
152,CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1,Fenofibrate,-,negative
153,NCCCC(=O)O,Aminobutyric Acid,2D6-Substrate,negative
154,CN1CCC[C@H]1c1cccnc1,Nicotine,2E1-Inducer,negative
155,CC[N+](C)(CC)CCc1c(C)c2ccc(OC)cc2oc1=O,AMMC,2D6-Substrate,negative
156,CCOC(=O)CN[C@@H](C(=O)N1CC[C@H]1C(=O)NCc1ccc(C=NNO)cc1)C1CCCCC1,Ximelagatran,2C9-Substrate,negative
157,CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O,Benzylpenicillin,Canalicular_multispecific_organic_anion_transporter_1-Inducer,negative
158,CC12CCC(O)CC1=CCC1C2CCC2(C)C(c3cccnc3)=CCC12,Abiraterone,-,negative
159,Clc1ccc2nsnc2c1NC1=NCCN1,Tizanidine,1A2-Substrate,negative
160,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CCC2=O,Estrone,4A11-Substrate,negative
161,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O,Piroxicam,-,negative
162,CCCc1nc(C)c2c(=O)nc(-c3cc(S(=O)(=O)N4CCN(CC)CC4)ccc3OCC)[nH]n12,Vardenafil,HLp2-Substrate,negative
163,CC(C)NNC(=O)c1ccncc1,Iproniazide,N_acetyltransferase-Inhibitor,negative
164,Nc1nc(OCc2ccccc2)c2nc[nH]c2n1,O6_benzylguanine,1A2-Substrate,negative
165,Clc1ccc2c(c1)C(c1ccccc1)=NCc1nncn1-2,Estazolam,3A4-Substrate,negative
166,Fc1ccc(C(c2ccc(F)cc2)N2CCN(CC=Cc3ccccc3)CC2)cc1,Flunarizine,GST-Inducer,negative
167,N[Pt](N)(Cl)Cl,Cisplatin,Probable_low_affinity_copper_uptake_protein_2-Substrate,negative
168,Cc1ccsc1C(=CCCN1CCC[C@@H](C(=O)O)C1)c1sccc1C,Tiagabine,2D6-Substrate,negative
169,CCN(CC)C(=O)NC1CC2c3cccc4[nH]cc(c34)CC2N(C)C1,Terguride,2D6-Substrate,negative
170,CS(C)=O,Dimethyl Sulfoxide,2D6-Inhibitor,negative
171,C=C(C)[C@@H]1CC=C(C)CC1,limonene_S,2C19-Substrate,negative
172,COc1ccc(C(c2ccc(O)c(O)c2)C(Cl)(Cl)Cl)cc1,catechol_methoxychlor,2D6-Substrate,negative
173,C=CC1CN2CCC1CC2C(O)c1ccnc2ccc(OC)cc12,Quinine,-,negative
174,C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,Prednisolone,3A4-Inducer,positive
175,FC(F)OC(F)(F)C(F)Cl,enflurane,2E1-Substrate,negative
176,CCCCc1nc(Cl)c(C=O)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,losartan_carboxaldehyde_EXP_3179,2C9-Substrate,negative
177,CNS(=O)(=O)Cc1ccc2[nH]cc(CCCN3CCN(c4ncncc4OC)CC3)c2c1,Avitriptan,2D6-Substrate,negative
178,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,Acarbose,2E1-Inducer,negative
179,Cc1ccccc1[C@H](OCCN(C)C)c1ccccc1,Orphenadrine (citrate),2D6-Inhibitor,negative
180,CC(c1cc2ccccc2s1)N(O)C(N)=O,Zileuton,-,negative
181,O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3[C@H]2C1,Praziquantel,P450_HFLA-Substrate,negative
182,O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1,Domperidone,P450_HFLA-Substrate,negative
183,CN(C)CCC=C1c2ccccc2COc2ccccc21,Doxepin,GST-Inhibitor,negative
184,C=C[C@H]1CN2CC[C@H]1C[C@@H]2[C@@H](O)c1ccnc2ccc(OC)cc12,Quinidine,3A4-Inducer,positive
185,C[C@H](NCCc1ccc(O)cc1)[C@H](O)c1ccc(O)cc1,Ritodrine,SUL-Substrate,negative
186,C[C@]12CCC(=O)C=C1CC[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C=O)[C@@H](C(=O)CO)CC[C@@H]12,Aldosterone,Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inducer,negative
187,FCOC(C(F)(F)F)C(F)(F)F,Sevoflurane,2E1-Substrate,negative
188,CCc1ccc(CCOc2ccc(C[C@@H]3SC(=O)NC3=O)cc2)nc1,Pioglitazone,3A4-Inducer,positive
189,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,Gefitinib,2D6-Inhibitor,negative
190,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1,Tamsulosin,2D6-Substrate,negative
191,COc1cc2[nH]c(C)c(CCN3CCN(c4ccccc4)CC3)c2cc1OC,Oxypertine,Canalicular_multispecific_organic_anion_transporter_2-Inducer,negative
192,C[C@H](CN(C)C)CN1c2ccccc2CCc2ccccc21,Trimipramine,2D6-Substrate,negative
193,CCCCCCOc1ccc2ccc(=O)oc2c1,7_hexoxy_coumarin,3A4-Substrate,negative
194,NNCCc1ccccc1,Phenelzine,P450_HFLA-Inhibitor,negative
195,CN[C@H](C)Cc1ccccc1,methamphetamine_R,2D6-Substrate,negative
196,CCCCCCCCCCCCCC(=O)O,myristic_acid,2E1-Substrate,negative
197,NC(=O)NO,Hydroxycarbamide,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
198,CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1cccc(Cl)c1Cl,Clevidipine,2C9-Inhibitor,negative
199,CC(C)Oc1ccc2c(=O)c(-c3ccccc3)coc2c1,Ipriflavone,2E1-Inducer,negative
200,O=C1CN=C(c2ccccc2F)c2cc(Cl)ccc2N1CC(F)(F)F,2_oxo_quazepam,2C9-Substrate,negative
201,c1ccc(C2(N3CCCCC3)CCCCC2)cc1,Phencyclidine,-,negative
202,CC(=O)OCC[N+](C)(C)C,Acetylcholin,Methyltransferase-Inducer,negative
203,CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12,Mitomycin,1A2-Inducer,negative
204,CCOC(C)(C)C,ethyl_tert_butyl_ether,2E1-Substrate,negative
205,CCC(C)(C)OC,tert_amyl_methyl_ether,2E1-Substrate,negative
206,Cn1c(=O)[nH]c2ncn(C)c2c1=O,Paraxanthine,-,negative
207,O=C1C2CCCCC2C(=O)N1CCCCN1CCN(c2nsc3ccccc23)CC1,Perospirone,2D6-Substrate,negative
208,COC(=O)C1=C(C)NC(C)=C(C(=O)O[C@@H]2CCCN(Cc3ccccc3)C2)[C@H]1c1cccc([N+](=O)[O-])c1,Benidipine,2D6-Inhibitor,negative
209,CN(CC=CC#CC(C)(C)C)Cc1cccc2ccccc12,Terbinafine,3A4-Inducer,positive
210,C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)C[C@@H](O)C[C@@H]1O,1_alpha_hydroxy_vitamin_D2,3A4-Substrate,negative
211,Cc1cc2ccccc2c2ccc3ccccc3c12,5_methylchrysene,2E1-Substrate,negative
212,Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,Zolpidem,P450_HFLA-Substrate,negative
213,C[C@@](N)(Cc1ccc(O)c(O)c1)C(=O)O,Methyldopa (levorotatory),GST-Inhibitor,negative
214,O=C(O)COc1ccc(C(=O)c2cccs2)cc1,suprofen_desmethyl,2C9-Substrate,negative
215,C#CCN(C)[C@H](C)Cc1ccccc1,Selegiline,2E1-Inhibitor,negative
216,CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,Duloxetine,2D6-Substrate,negative
217,COc1ccc(-c2nc3ccc(C4=NNC(=O)CC4C)cc3[nH]2)cc1,Pimobendan,-,negative
218,CCCCN(CCCC)CC[C@@H](O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12,halofantrine_R,2C8-Substrate,negative
219,CN(C)CCC=C1c2ccccc2COc2ccc(CC(=O)O)cc21,Olopatadine,-,negative
220,CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1,Vecuronium,Methyltransferase-Inhibitor,negative
221,COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,Etoposide,3A4-Inducer,positive
222,CCc1cccc2cc(C(O)CNC(C)(C)C)oc12,Bufuralol,2D6-Substrate,negative
223,Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O,Febuxostat,UGT-Substrate,negative
224,CNC[C@H](O)c1ccc(O)c(O)c1,Epinephrine,SUL-Substrate,negative
225,CC(=O)Nc1nnc(S(N)(=O)=O)s1,Acetazolamide,-,negative
226,C[C@@H]1C[C@H]2[C@H]3CCC4=CC(=O)C=C[C@@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,Clobetasol,1A2-Inhibitor,negative
227,CCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,Testosterone,3A4-Inducer,positive
228,O=[P@@]1(N(CCCl)CCCl)OCCCN1CCCl,Trofosfamide,-,negative
